Media formats available:
Recommended
- Inflammation: The next therapeutic frontier in targeting cardiovascular riskThe journey from hypothesis to reality on inflammation in CVD
Prof. Peter Libby, MD
prof. Paul Ridker, MD
- Inflammation: The next therapeutic frontier in targeting cardiovascular riskIL-6 as therapeutic target in inflammation and CVD
Prof. Peter Libby, MD
- Inflammation: The next therapeutic frontier in targeting cardiovascular risk3 Challenges when targeting inflammation in residual CV risk
Prof. Filippo Crea, MD
- Inflammation: The next therapeutic frontier in targeting cardiovascular riskImmunity and inflammation in atherosclerosis - no longer just a theory
prof. Paul Ridker, MD